Delaying Cancer Cases in Urology during COVID-19: Review of the Literature. Reply.

You have accessJournal of UrologyLetters to the Editor/Errata1 May 2021Delaying Cancer Cases in Urology during COVID-19: Review Literature. Reply.is a reply letterDelaying Letter. Isamu Tachibana and Chandru P. Sundaram TachibanaIsamu Indiana University School Medicine, Indianapolis, More articles by this author SundaramChandru * E-mail Address: [email protected] View All Author Informationhttps://doi.org/10.1097/JU.0000000000001644AboutPDF ToolsAdd favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail To Editor: We appreciate comments read with great interest impact COVID on medical care Italy. The economic burden can be significant setting metastatic disease not only for systems but individuals axitinib-pembrolizumab having mean cost $562,927 or nivolumab-ipilimumab $458,961 United States.1 factors, including clinical staging, appearance imaging, nephrometry score, history renal mass biopsy should considered treat patients while is still localized, avoid increasing risk progression. Renal does role cases where results could provide information that would decision making regarding indication surgery potential delay surgery. biopsies high success rates as mentioned, when compared nomograms, are superior confirm pathology.2 However, there some caveats consider diagnostic ability biopsy. Diagnostic been affected smaller masses, longer skin tumor distance, cystic less enhancement contrast images.3 Another potentially worrisome issue may possible discordance grade malignancy final surgical specimen. In terms tumor, studies shown accuracy ranges from 51.2% 75.9%, upgrading 16% low pathology specimen.4 certainly contribute evaluating management masses risk-stratify identify who at higher risk. If aggressive signs disease, aside biopsy, it prudent proceed intervention select cases. Surgical delays continue challenges hospital priority make sure negatively delays. References 1. : Cost-effectiveness pembrolizumab plus axitinib vs nivolumab ipilimumab first-line treatment advanced cell carcinoma US.JAMA Netw Open 2020; 3: e2016144. Google Scholar 2. Comparison percutaneous R.E.N.A.L. score nomograms determining benign malignant low-risk high-risk tumors.Urology 2016; 96: 87. 3. Patient characteristics predict nondiagnostic findings.J Urol 2015; 193: 1899. Link, 4. Systematic review meta-analysis tumour biopsy.Eur 69: 660. © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal Urology19 Feb Volume 205Issue 5May 2021Page: 1536-1536 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand PDF downloadLoading ...